Preclinical neuroscience firm Delix Therapeutics Inc., a startup developing non-hallucinogenic analogues of psychedelics, has closed a $70 million series A financing. The new funds will help the Boston-based company advance two lead candidates through phase I trials, DLX-1 and DLX-7, with studies planned for starts in late 2022 or early 2023.
Hexagon Bio Inc.’s latest, $61 million financing to advance work with small molecules mined from microbial genomes will help the firm build its DNA database, add to the team and advance preclinical work, said CEO Maureen Hillenmeyer.
LONDON – There were well-deserved celebrations in Paris on Sept. 20, as Jeito Capital toasted the oversubscribed close of its first fund at €534 million (US$625.5 million). This is claimed as the largest European venture fund dedicated to life sciences, exceeding the original target of €500 million, and with €340 million of the total raised under the constraints of the pandemic from January 2020 onward.
DUBLIN – Treefrog Therapeutics SA closed a $75 million series B round this week, which will help to increase its reach and its profile, as it pursues its highly ambitious objective to drive the adoption of a new way of making induced pluripotent stem cells (iPSCs) at scale. The Bordeaux, France-based firm is not a CDMO in any sense, however. It is a fully fledged biotech, with early stage iPSC-based programs in Parkinson’s disease, cardiovascular disease and bone marrow transplant, among others. It’s just that it is also attempting to revolutionize how those cells are cultivated before it administers them as therapies.